© 2022 Vial. All rights reserved
- Nonalcoholic fatty liver disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
- Objective Endpoints
- Office for Human Research Protection (OHRP)
- Open-Label Trial
- Optic Nerve
- Over-the-Counter (OTC) Applications
- Parkinson’s Disease
- PASI Score
- Pediatric Neurology
Non-Alcoholic Steatohepatitis (NASH)
What is NASH? Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver disease (NAFLD). It's a metabolic syndrome characterized by damage to the liver by inflammation and apoptosis caused by excessive infiltration of triglycerides. As the clinical presentation of NASH is nonspecific, diagnosis is usually delayed.
NAFLD is the most common form of liver disease worldwide, affecting over 25% of the adult population, with an increasing incidence. NASH affects 3-6% of the US population and is one of the leading causes of liver fibrosis, cirrhosis and hepatocellular carcinoma, resulting in increased burden of morbidity and mortality associated with the liver. There is currently no FDA-approved treatment for NASH.
- Risk factors for development of NASH include:
- Middle Eastern and Hispanic ethnicity
- Male sex
- Associated comorbid conditions, such as obesity (especially central), type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension, and metabolic syndrome.
Source: Sheka, A. C. (2020). Nonalcoholic Steatohepatitis A Review. JAMA, 323(12), 1175–1183. https://doi.org/10.1001/jama.2020.2298